|
|
|
24.10.25 - 11:33
|
XFRA: 63E: Wiederaufnahme/Resumption (XETRA)
|
|
|
FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.
THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN
ONWARD MEDICAL BV EO -,12 63E NL0015000HT4
AB/FROM ONWARDS 24.10.2025 11:16 CET...
|
|
|
|
|
23.10.25 - 09:45
|
XFRA: 63E: Aussetzung/Suspension (XETRA)
|
|
|
DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:
THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL
ONWARD MEDICAL BV EO -,12 63E NL0015000HT4 BAW/UFN...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
06.08.25 - 20:30
|
ONWARD Medical gibt Ernennung von Lucas Buchanan als Vorstandsmitglied bekannt (GlobeNewswire)
|
|
|
EINDHOVEN, Niederlande, Aug. 06, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD und US OTCQX: ONWRY), das führende Neurotechnologieunternehmen, das Pionierarbeit bei Therapien zur Wiederherstellung der Bewegungsfähigkeit, Funktion und Unabhängigkeit von Menschen mit Rückenmarksverletzungen (Spinal cord injury, SCI) und anderen Bewegungseinschränkungen leistet, gibt heute die Ernennung von Lucas Buchanan als nicht geschäftsführendes Mitglied seines Vorstands bekannt....
|
|
|
06.08.25 - 07:33
|
ONWARD Medical Announces the Appointment of Lucas Buchanan to its Board of Directors (GlobeNewswire EN)
|
|
|
EINDHOVEN, The Netherlands, Aug. 06, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD and US OTCQX: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injury (SCI) and other movement disabilities, today announces the appointment of Lucas Buchanan as a non-executive member of its Board of Directors....
|
|
|
|
|
01.07.25 - 07:33
|
ONWARD Medical Files 510(k) with US FDA for ARC-EX System Home Use and Submits CE Mark Application (GlobeNewswire EN)
|
|
|
EINDHOVEN, the Netherlands, July 01, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD and US OTCQX: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injury (SCI) and other movement disabilities, today announced the submission of two major regulatory applications for its ARC-EX System. The Company has submitted a 510(k) application to the US Food and Drug Administration (FDA) seeking clearance to expand its indication for home use. In parallel, ONWARD has filed an application with the notified body for CE Mark certification in accordance with the European Union Medical Device Regulation (MDR) to enable commercialization of the ARC-EX System in the EU. Completed in June, these submissions represent significant milestones as the Company advances its mission to bring breakthrough therapies to people with SCI around the world....
|
|
|
|
|
|
|
|
|
21.05.25 - 07:33
|
ONWARD Medical Advances Brain-Computer Interface Leadership with Fourth and Fifth Successful BCI Implants (GlobeNewswire EN)
|
|
|
EINDHOVEN, the Netherlands, May 21, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD and US OTCQX: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function and independence in people with spinal cord injury (SCI) and other movement disabilities, today announces that two additional individuals with spinal cord injury have received ONWARD's investigational ARC-BCI® Therapy, bringing the total number of successful implants to five....
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
